Abstract:e13651 Background: With the general application of EGFR TKI in treatment for NSCLC, more and more adherent and acquired resistance to such agents happens. To further improve efficacy of this kind of agents, a better understanding of the mechanism of resistance is necessary. Methods: Gefitinib-resistant PC9/G cell lines was induced by exposure of PC9 cell lines to MNNG and gefitinib and maintained in the mediua containing 0.05 umol/L of gefitinib. The inhibitory effects of gefitinib and/or LY294002 and PD98059 on cellular proliferation were tested by MTT assay. Cell cycle and apoptosis were analyzed by flow cytometry. Western Blot was used to detect expression of EGFR, phospho-EGFR, Akt and phospho-Akt. The different profiles of gene expression between PC9 and PC9/G cells were obtained by DNA microarray. β1 integrin was knocked down by transiently transfected siRNA. A scrambled sequence was used as control. The sensitivity to gefitinib of transfected cells was determined by MTT assay. Sequencing products were amplified by nested PCR. Apoptosis of transfected cells was assayed by TUNEL methods. Results: Resistant index of PC9/G to gefitinib was about 140 to 241 fold compared with PC9.Overexpression of β1 integrin was observed in PC9/G. Depletion of β1 integrin with shRNA results in inhibition of proliferation and promotion of apoptosis of PC9/G. Phosphorylation of Akt was less inhibited by gefitinib in PC9/G than in PC9. The restoration of sensitivity of PC9/G to gefitinib by LY294002, PI3-K inhibitor, and the diminished level of phospho-Akt induced by knock down of β1 integrin with RNAi. Conclusions: These findings suggest that β1 integrin signaling through PI3-K may be an important mechanism of resistance to EGFR TKIs and β1 integrin may be a therapeutic target for treatment of NSCLC unresponsive to EGFR inhibitors. No significant financial relationships to disclose.

Supplementary Figure 5 from Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 7 from Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

Supplementary Figure 5 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 4 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Β-Catenin Overexpression is Associated with Gefitinib Resistance in Non-Small Cell Lung Cancer Cells.

Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Methods from AZ1366: an Inhibitor of Tankyrase and the Canonical Wnt Pathway That Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Supplementary Figure from <i>FOXM1</i> Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer

Supplementary Figure 6 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Information, Figures 1-10 from Inhibition of Gastric Cancer Invasion and Metastasis by PLA2G2A, a Novel Β-Catenin/tcf Target Gene

Supplementary Figures 1 - 10 from Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants is Associated with Asymmetric Dimerization

Supplementary Figure 5 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2